On October 26, 2021 PCI Biotech (OSE: PCIB), a clinical-stage biopharma company developing innovative therapeutics that address significant unmet medical needs in cancer reported that the first Asian patient in the fimaChem pivotal RELEASE study with registration intent in inoperable bile duct cancer patients has been enrolled in South Korea (Press release, PCI Biotech, OCT 26, 2020, View Source [SID1234585151]). The RELEASE study spans across Europe, USA and Asia, following the recent opening of several clinical sites in both South Korea and Taiwan.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!